Mabtech, a Swedish life science tools company developing immunoassay biochemical tests for research, announces a new highly innovative image-based multiplex platform in close collaboration with research and technology specialist Qamcom.
Beckman Coulter Life Sciences introduces the Next-Generation Basophil Activation Test (BAT) for research use only to more effectively characterise allergies without exposure to potentially harmful allergens.
Aelius Biotech, whose laboratory gut model is used to trial new drugs without the need for animal testing has raised £750,000 from the North East Venture Fund, supported by the European Regional Development Fund and managed by Mercia Ventures.
In its largest-ever funding initiative for early-career researchers, the Academy of Medical Sciences is investing £7.6 million to tackle urgent health challenges from Alzheimer’s disease, cancer and obesity to addiction and climate change impacts.
AMSBIO has expanded its biofluid collection and processing capabilities, to now offer a range of customisable human blood biospecimens from both healthy and disease-state donors to support biomedical research.
Sapio Sciences, the science-aware lab informatics platform, has announced the integration of the NVIDIA BioNeMo platform into the Sapio Lab Informatics Platform.
Beckman Coulter Life Sciences and an Operating Company of Danaher Corporation, "revolutionises" spectral flow cytometry with the industry’s first modular solution: the CytoFLEX mosaic Spectral Detection Module.
Beckman Coulter Life Sciences in partnership with Rarity Bioscience AB offers a new approach to oncology research by extending the capabilities of flow cytometry to clinical molecular research.
OncoHost has announced a collaboration with Gustave Roussy, the first European cancer centre, to identify non-invasive biomarkers for immune-related adverse events (irAEs) in patients undergoing immunotherapy.
Oxford Drug Design has been awarded £1m in funding to progress its uUTI (uncomplicated urinary tract infection) antibacterial programme, as announced by PACE (Pathways to Antimicrobial Clinical Efficacy).
Infex Therapeutics, an anti-infectives specialist, has announced that in collaboration with Justus-Liebig-University Giessen, it has been awarded a £1 million grant from PACE, to develop a BamA inhibitor.
